Allurion Technologies Holdings Inc. has announced the publication of a peer-reviewed multicenter study evaluating the consecutive use of the Allurion Smart Capsule, a swallowable, procedure-less weight-loss device. The study, which included participants from six countries, demonstrated that two consecutive treatments with the Smart Capsule resulted in weight loss exceeding 20% of body weight. According to the company, these results are comparable to those achieved with bariatric surgery and high-dose GLP-1 therapy. The study results have already been published and add to the existing data supporting the safety and efficacy of the device. Allurion has also submitted the final module of its Pre-Market Approval (PMA) application to the U.S. Food and Drug Administration (FDA) based on the findings of the AUDACITY trial.